According to the report, the global acute lymphoblastic leukemia market size is expected to hit around US$ 3,278.8 million by 2027 and projected to expand at a CAGR of 8.2% from 2020 to 2027. Expansion of the pharmaceutical industry, government initiatives, increase in health care expenditure, surge in research & development, and rise in patient population are anticipated to augment the global market from 2020 to 2027.
Increase in Patient Population to Propel Market
Acute lymphoblastic leukemia, one of four major types of leukemia, is a blood cancer that starts in the bone marrow and spreads into the blood, rapidly. Acute lymphoblastic leukemia is an aggressive type of leukemia, which requires early treatment; without treatment, most patients with acute leukemia would live only a few months. Acute lymphoblastic leukemia is more common among children aged above five. Increase in patient population for acute lymphoblastic leukemia propels the market. According to recent study, around 412,000 people worldwide are likely to be diagnosed with some type of leukemia, and acute lymphoblastic leukemia accounts for approximately 12% of all leukemia cases worldwide. According to the American Society of Clinical Oncology (ASCO), nearly 5,970 cases of acute lymphoblastic leukemia (ALL) were reported in the U.S. in 2017.
Rise in Number of New Product Approvals and Clinical Trials
Demand for therapeutics for acute lymphoblastic leukemia has increased in the last few years. This has resulted in the rise in new product approval and number of clinical trials in late and early phases of drug development. For instance, in August 2018, Novartis AG received approval from the European Commission for its CAR-T cell therapy (Kymriah) for B-cell acute lymphoblastic leukemia. For instance, in 2017, Baylor College of Medicine started conducting phase 1 clinical trials of CD5.CAR/28zeta CAR T cells, Cytoxan for T-cell acute lymphoblastic leukemia. The study is expected to be complete by June 1, 2036.
High Cost of Treatment to Restrain Market
Rise in scientific and technological advancements in R&D and manufacturing processes is projected to increase the efficiency of drug development. However, high cost associated with the treatment of acute lymphoblastic leukemia is anticipated to restrain the market during the forecast period. Development of therapeutics require the utilization of expensive instrumentation, which in turn increases the overall cost of therapeutics and treatment for the disease. For instance, the cost of chemotherapeutic Arranon (Nelarabine) is between US$ 75,000 and US$ 100,000 in the U.S.
Asia Pacific Market to Expand Significantly
In terms of revenue, the acute lymphoblastic leukemia market in Asia Pacific is projected to expand at a high CAGR during the forecast period. Rapidly increasing patient population in the region is expected to boost the demand for therapeutics for the treatment of acute lymphoblastic leukemia. This, in turn, is likely to drive the market from 2020 to 2027. Increase in government expenditure on health care is anticipated to fuel the acute lymphoblastic leukemia market in Asia Pacific during the forecast period. For instance, according to India’s Union Budget 2019–2020, the total health care expenditure was increased from 1.97% to 2.27% of the total union budget.
Novartis AG and Pfizer, Inc. to Lead Market
The report also provides profiles of leading players operating in the global acute lymphoblastic leukemia market. These include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma, Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc. Increase in mergers & acquisitions, strategic collaborations, surge in clinical trials, and new product launches are expected to drive the global market during the forecast period. For instance, in January 2017, Novartis AG signed collaborative agreements with various key industry players to co-develop and co-commercialize oncology therapies.
The report analyzes and forecasts the acute lymphoblastic leukemia market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of acute lymphoblastic leukemia, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major acute lymphoblastic leukemia companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of acute lymphoblastic leukemia upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of acute lymphoblastic leukemia and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global acute lymphoblastic leukemia market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the acute lymphoblastic leukemia market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of acute lymphoblastic leukemia market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the global acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
4.3. Global Acute Lymphoblastic Leukemia Market Outlook
4.4. Key Industry Developments
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global Acute Lymphoblastic Leukemia Market, by Type
6.1. Introduction
6.2. Global Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
6.3. Global Acute Lymphoblastic Leukemia Market Value Forecast, by Type
6.4. Global Acute Lymphoblastic Leukemia Market Analysis, by Type
6.4.1. B-cell
6.4.2. T-cell
7. Global Acute Lymphoblastic Leukemia Market, by Treatment
7.1. Key Findings
7.2. Introduction
7.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment
7.4. Global Acute Lymphoblastic Leukemia Market Forecast, Treatment
7.5. Global Acute Lymphoblastic Leukemia Market Analysis, by Treatment
7.5.1. Chemotherapy
7.5.2. Radiation Therapy
7.5.3. Bone Marrow Transplant
7.5.4. Targeted Therapy
7.5.5. Immunotherapy
7.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment
8. Global Acute Lymphoblastic Leukemia Market, by End-user
8.1. Key Findings
8.2. Introduction
8.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
8.4. Global Acute Lymphoblastic Leukemia Market Forecast, by End-user
8.5. Global Acute Lymphoblastic Leukemia Market Analysis, by End-user
8.5.1. Hospitals
8.5.2. Clinics
8.5.3. Others
8.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
9. Acute Lymphoblastic Leukemia Market Analysis, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
9.4. Global Acute Lymphoblastic Leukemia Market Forecast, by Region
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East & Africa
9.5. Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region
10. North America Acute Lymphoblastic Leukemia Market
10.1. Key Findings
10.2. North America Acute Lymphoblastic Leukemia Market Overview
10.3. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
10.4. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
10.6. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
10.6.1. B-cell
10.6.2. T-cell
10.7. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
10.8. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
10.8.1. Chemotherapy
10.8.2. Radiation Therapy
10.8.3. Bone Marrow Transplant
10.8.4. Targeted Therapy
10.8.5. Immunotherapy
10.9. North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
10.10. North America Acute Lymphoblastic Leukemia Market Forecast, End-user
10.10.1. Hospitals
10.10.2. Clinics
10.10.3. Others
10.11. North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
11. Europe Acute Lymphoblastic Leukemia Market
11.1. Key Findings
11.2. Europe Acute Lymphoblastic Leukemia Market Overview
11.3. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
11.6. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Type
11.6.1. B-cell
11.6.2. T-cell
11.7. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
11.8. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
11.8.1. Chemotherapy
11.8.2. Radiation Therapy
11.8.3. Bone Marrow Transplant
11.8.4. Targeted Therapy
11.8.5. Immunotherapy
11.9. Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
11.10. Europe Acute Lymphoblastic Leukemia Market Forecast, End-user
11.10.1. Hospitals
11.10.2. Clinics
11.10.3. Others
11.11. Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
12. Asia Pacific Acute Lymphoblastic Leukemia Market
12.1. Key Findings
12.2. Asia Pacific Acute Lymphoblastic Leukemia Market Overview
12.3. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
12.6. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Type
12.6.1. B-cell
12.6.2. T-cell
12.7. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
12.8. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
12.8.1. Chemotherapy
12.8.2. Radiation Therapy
12.8.3. Bone Marrow Transplant
12.8.4. Targeted Therapy
12.8.5. Immunotherapy
12.9. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
12.10. Asia Pacific Acute Lymphoblastic Leukemia Market Forecast, End-user
12.10.1. Hospitals
12.10.2. Clinics
12.10.3. Others
12.11. Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
13. Latin America Acute Lymphoblastic Leukemia Market
13.1. Key Findings
13.2. Latin America Acute Lymphoblastic Leukemia Market Overview
13.3. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
13.6. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
13.6.1. B-cell
13.6.2. T-cell
13.7. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
13.8. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
13.8.1. Chemotherapy
13.8.2. Radiation Therapy
13.8.3. Bone Marrow Transplant
13.8.4. Targeted Therapy
13.8.5. Immunotherapy
13.9. Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
13.10. Latin America Acute Lymphoblastic Leukemia Market Forecast, End-user
13.10.1. Hospitals
13.10.2. Clinics
13.10.3. Others
13.11. Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
14. Middle East & Africa Acute Lymphoblastic Leukemia Market
14.1. Key Findings
14.2. Middle East & Africa Acute Lymphoblastic Leukemia Market Overview
14.3. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Country
14.4.1. GCC Countries
14.4.2. Israel
14.4.3. South Africa
14.4.4. Rest of Middle East & Africa
14.5. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
14.6. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Type
14.6.1. B-cell
14.6.2. T-cell
14.7. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
14.8. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
14.8.1. Chemotherapy
14.8.2. Radiation Therapy
14.8.3. Bone Marrow Transplant
14.8.4. Targeted Therapy
14.8.5. Immunotherapy
14.9. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
14.10. Middle East & Africa Acute Lymphoblastic Leukemia Market Forecast, End-user
14.11. Hospitals
14.12. Clinics
14.13. Others
14.14. Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
15. Competition Landscape
15.1. Acute Lymphoblastic Leukemia Market Share Analysis, by Company
15.2. Competition Matrix
15.3. Company Profile
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Erytech Pharma Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. CELGENE CORPORATION
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Amgen, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Bristol-Myers Squibb Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Spectrum Pharmaceuticals, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers